Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses Abstract #2078

Introduction: In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.
Aim(s): Assess what side effects patients report after starting SSA. Assess the severity of side effects reported by patients after starting SSA. Produce recommendations on how to deal with side effects of SSA’s.
Materials and methods: A survey was created using SurveyMonkey and then posted on social media (twitter), within a closed NET patient support group and an open advocacy site. It was open to anyone worldwide. Patients were asked 2 questions: 1) Which somatostatin analogue has been prescribed. 2) Rate the severity (0-10) of any side effects they have experienced. A list of 11 options was given: constipation, steatorrhoea, diarrhoea, feeling the burden of treatment, vitamin B12 deficiency, hair thinning, nausea, fat soluble vitamin deficiency, weight loss, low glucose level and gallstones. They were not given any guidance or definitions of terms.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tara Whyand

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1525 Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education
Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Philippa Davies
Authors: Davies P, ,
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#1593 Role of SSA in the Management of Multiple Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 g-NENs associated with autoimmune chronic atrophic gastritis have high risk of recurrence but rare metastasis. Most type 1 patients are managed by endoscopic approach. The clinical benefit of somatostatin analogues (SSA) for type 1 g-NENs is controversial.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Huang-Ying Tan
Authors: Li Y L, Dou D, Tan H Y
Keywords: SSA, gastric nen, type 1
#2055 Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)
Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Faidon Laskaratos
#479 Efficacy and Safety of Everolimus in Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Everolimus is a treatment option for patients with pancreatic NETs, while its use in patients with gastrointestinal NETs still remains to be defined.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Maria Rosaria Ambrosio